CN101316582A - 治疗肌肉损失的方法 - Google Patents

治疗肌肉损失的方法 Download PDF

Info

Publication number
CN101316582A
CN101316582A CNA2006800445600A CN200680044560A CN101316582A CN 101316582 A CN101316582 A CN 101316582A CN A2006800445600 A CNA2006800445600 A CN A2006800445600A CN 200680044560 A CN200680044560 A CN 200680044560A CN 101316582 A CN101316582 A CN 101316582A
Authority
CN
China
Prior art keywords
bcaa
protein
product
rich
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800445600A
Other languages
English (en)
Chinese (zh)
Inventor
M·提斯达尔
N·A·格林博格
H·埃雷
K·B·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of CN101316582A publication Critical patent/CN101316582A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
CNA2006800445600A 2005-11-30 2006-11-28 治疗肌肉损失的方法 Pending CN101316582A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74109205P 2005-11-30 2005-11-30
US60/741,092 2005-11-30
US60/780,941 2006-03-09

Publications (1)

Publication Number Publication Date
CN101316582A true CN101316582A (zh) 2008-12-03

Family

ID=37806127

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800445600A Pending CN101316582A (zh) 2005-11-30 2006-11-28 治疗肌肉损失的方法

Country Status (17)

Country Link
US (1) US8329646B2 (https=)
EP (1) EP1957061B1 (https=)
JP (1) JP5260303B2 (https=)
CN (1) CN101316582A (https=)
AT (1) ATE508745T1 (https=)
AU (1) AU2006320670B8 (https=)
BR (1) BRPI0619179A2 (https=)
CA (1) CA2631647A1 (https=)
DK (1) DK1957061T3 (https=)
ES (1) ES2363442T3 (https=)
IL (1) IL191374A0 (https=)
MY (1) MY147489A (https=)
PT (1) PT1957061E (https=)
RU (1) RU2414897C2 (https=)
SG (1) SG163600A1 (https=)
WO (1) WO2007064618A1 (https=)
ZA (1) ZA200805657B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105747214A (zh) * 2016-02-26 2016-07-13 四川安益生物科技有限公司 一种支链氨基酸组合物
CN107440126A (zh) * 2017-09-08 2017-12-08 天津活力达生物科技有限公司 一种缓解运动疲劳的蛋白粉及其制备方法
CN112839528A (zh) * 2018-04-18 2021-05-25 独创成分有限合伙公司 用于促进肌肉生长和功能的组合物及其使用方法
CN113924120A (zh) * 2019-06-20 2022-01-11 雀巢产品有限公司 增强一种或多种合成代谢氨基酸的肌肉骨骼效应的组合物和方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
US20110077198A1 (en) * 2007-11-26 2011-03-31 Michael John Tisdale Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
CN101939011B (zh) 2008-02-07 2012-10-10 雀巢产品技术援助有限公司 用于影响由剧烈的体力活动中恢复的组合物和方法
US20090264363A1 (en) * 2008-03-26 2009-10-22 Ward Loren S Leucine-Rich Peptide Compositions and Methods for Isolation
US20130236447A1 (en) * 2008-12-23 2013-09-12 Carmel-Haifa University Economic Corp., Ltd. Cognitive function
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
US20130330423A1 (en) * 2011-02-25 2013-12-12 Merck Patent Gmbh Composition to increase joint and/or postural stability
RU2454227C1 (ru) * 2011-04-05 2012-06-27 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Композиция для восстановления скелетных мышц и кости при скелетной травме
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
CA2863809A1 (en) * 2012-02-06 2013-08-15 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
US9700071B2 (en) 2012-03-26 2017-07-11 Axcella Health Inc. Nutritive fragments, proteins and methods
RU2634407C2 (ru) 2012-03-26 2017-10-26 Эксселла Хелт Инк. Фрагменты пищевых белков и способы их применения
EP2831098A4 (en) 2012-03-26 2016-12-07 Axcella Health Inc LOADED NUTRIENT PROTEINS AND METHODS
EP2831100A4 (en) 2012-03-26 2016-02-10 Pronutria Inc NUTRIENT PROTEINS AND METHOD
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
RU2517576C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Средство для профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
HK1221609A1 (zh) * 2013-05-01 2017-06-09 Abbott Laboratories 增强老化肌肉再生的方法
CN103416760B (zh) * 2013-08-28 2014-09-10 山东卫康生物医药科技有限公司 治疗和预防肌肉衰减综合症的五谷杂粮全营养配方食品
RU2016110800A (ru) 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
KR101668074B1 (ko) * 2015-02-12 2016-10-21 전북대학교산학협력단 Ｐｋｒ 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물
JP7077235B2 (ja) * 2016-12-05 2022-05-30 大塚製薬株式会社 筋萎縮抑制組成物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
IT201900010437A1 (it) * 2019-06-28 2020-12-28 Dompe Farm Spa Composizione per il trattamento del deperimento muscolare

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US4677121A (en) 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
JPH03264525A (ja) * 1990-03-14 1991-11-25 Otsuka Pharmaceut Factory Inc アミノ酸輸液
US6608109B2 (en) 1991-11-20 2003-08-19 Allen Ann De Wees Composition comprising L-arginine as a muscle growth stimulant and use thereof
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
MXPA01002173A (es) * 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.
US6051236A (en) * 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
CZ20022927A3 (cs) 2000-02-01 2003-06-18 Muscletech Research And Development Inc. Doplňky stravy založené na alfa-lipoové kyselině pro zvýšení čisté svalové hmoty a síly
US7199124B2 (en) * 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
FR2833012B1 (fr) 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20080058324A1 (en) * 2004-08-25 2008-03-06 Santhera Pharmaceuticals (Schweiz) Ag Alpha-Keto Carbonyl Calpain Inhibitors
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
US7790688B2 (en) * 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105747214A (zh) * 2016-02-26 2016-07-13 四川安益生物科技有限公司 一种支链氨基酸组合物
CN107440126A (zh) * 2017-09-08 2017-12-08 天津活力达生物科技有限公司 一种缓解运动疲劳的蛋白粉及其制备方法
CN112839528A (zh) * 2018-04-18 2021-05-25 独创成分有限合伙公司 用于促进肌肉生长和功能的组合物及其使用方法
CN113924120A (zh) * 2019-06-20 2022-01-11 雀巢产品有限公司 增强一种或多种合成代谢氨基酸的肌肉骨骼效应的组合物和方法

Also Published As

Publication number Publication date
AU2006320670B8 (en) 2011-04-07
ZA200805657B (en) 2009-12-30
DK1957061T3 (da) 2011-07-25
ES2363442T3 (es) 2011-08-04
AU2006320670B2 (en) 2010-12-09
US20090105123A1 (en) 2009-04-23
EP1957061B1 (en) 2011-05-11
PT1957061E (pt) 2011-07-06
RU2414897C2 (ru) 2011-03-27
WO2007064618A8 (en) 2008-11-06
SG163600A1 (en) 2010-08-30
WO2007064618A1 (en) 2007-06-07
HK1118455A1 (en) 2009-02-13
AU2006320670A1 (en) 2007-06-07
CA2631647A1 (en) 2007-06-07
IL191374A0 (en) 2009-08-03
BRPI0619179A2 (pt) 2011-09-13
RU2008126294A (ru) 2010-01-10
JP5260303B2 (ja) 2013-08-14
JP2009517473A (ja) 2009-04-30
ATE508745T1 (de) 2011-05-15
MY147489A (en) 2012-12-14
EP1957061A1 (en) 2008-08-20
US8329646B2 (en) 2012-12-11

Similar Documents

Publication Publication Date Title
JP5260303B2 (ja) 筋肉損失の治療のための方法
US20110077198A1 (en) Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
US20080275120A1 (en) Leucine rich composition
Wang et al. Targeting cancer cachexia: Molecular mechanisms and clinical study
Yamauchi et al. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line
AU2018307712B2 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases
Fukuda et al. Adenine inhibits TNF-α signaling in intestinal epithelial cells and reduces mucosal inflammation in a dextran sodium sulfate-induced colitis mouse model
US20150328186A1 (en) Methods of Treating Hepatic Fibrosis and Associated Diseases by Regulating Rev-ERB Activity
JPWO2006061992A1 (ja) 肝疾患予防・治療用組成物
MX2008006902A (en) Methods for the treatment of muscle loss
HK1118455B (en) Combination comprising at least one amino acid and a pkr inhibitor for use in the treatment of muscle loss
KR20180016357A (ko) 종양에 대한 직접적인 억제 효과를 갖는 인터페론의 결정 방법 및 그 용도
Ohnuma* et al. Anorexia and cachexia
CN104825487A (zh) 治疗炎症性关节炎的组合物和方法
WO2006070874A1 (ja) 低酸素応答促進剤
Frietze et al. HIF-2α induction in de novo lipogenesis in metabolic dysfunction-associated steatohepatitis is dependent on IL-21 signaling.
Peng et al. Collagen III regulates the termination of liver regeneration by suppressing hepatocyte proliferation and promoting functional recovery
Cao et al. Anti-inflammatory effects of bitongling granules are mediated through the suppression of miR-21/p38 MAPK/TLR4/NF-κB signaling in H9C2 rat cardiac cells exposed to lipopolysaccharides
Canfield et al. Translational Medicine of Aging
Bossola et al. Gastric Cancer: A Model to Study Skeletal Muscle Wasting of Cachexia
Luo et al. Experimental immunology Inhibitory action of different doses of tripterygium hypoglaucum hutch on expression of hypoxia inducible factor-1α in collagen Ⅱ-induced arthritis rat model
CN113301902A (zh) 非酒精性脂肪肝病患者的纤维化的治疗和抑制

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20081203